Lilly CEO Has No Plans to Buy Amylin

Eli Lilly’s CEO told reporters in Los Angeles the Indianapolis-based pharmaceutical giant has no plans to acquire San Diego’s Amylin Pharmaceuticals—a sentiment that seems contrary to what dissident shareholders want. Billionaire investor Carl Icahn and Eastbourne Capital Management, which together hold more than 20 percent of Amylin shares, have been waging a proxy battle to gain control of Amylin (NASDAQ: AMLN). They apparently want to push for the sale of the diabetes drug developer to Lilly, which formed a partnership to market Amylin’s drugs. But Lilly (NYSE: LLY) CEO John Lechleiter says, “We like the relationship the way it is now,” and has no plans to acquire Amylin, according to Reuters.

Bruce V. Bigelow was the editor of Xconomy San Diego from 2008 to 2018. Read more about his life and work here. Follow @bvbigelow

Trending on Xconomy